News

The Phase IIa multicenter, double-blind, placebo-controlled study will enroll 150 pre-diabetic patients with impaired glucose tolerance, mild obesity and mild to moderate hypertension. All patients enrolled in the

This alliance sets the foundation for a clinical research project which will be conducted in Germany and in Canada under the direction of Andreas Pfutzner, who is the

The special protocol assessment (SPA) is a written agreement between the company, as the trial’s sponsor, and the FDA regarding the design, endpoints, and planned statistical analysis approach

Teva Parenteral Medicines’s (TPM) notice letter advised that it is seeking FDA approval to market daptomycin for injection prior to the expiration of two US patents, which expire

Under the agreement, Cumberland Emerging Technologies (CET) is providing formulation, grant funding, regulatory and product development assistance in exchange for rights to commercialize the new technology. The joint

The study, funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will be conducted by investigators at the Center

The first collaboration, with Harvard University, is based upon a new pain-drug-delivery technique that targets pain-sensing neurons without affecting motor neurons. Under the terms of the agreement, Endo

“During the quarter we prepared to initiate our two randomized Phase II trials for nimotuzumab, which concentrate on two forms of cancer typically treated with radiation-containing regimens. These

The company has reported data from the first of three cohorts in an ascending multiple dose study of MSI-1436 (Study 102). Data from cohort 1, in which eight